Top

RACE-2: long-term follow-up of patients participating in RACE: the prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for Severe Aplastic Anemia patients

Study type:

Non-interventional Prospective Studies

Study number:

84090088

Type of Stem Cell Treatment:

Diseases:

Bone marrow failure

Short title:

RACE-2: long-term follow-up

Primary objective:

To evaluate the long-term outcome and survival of patients who have received standard IST with or without Eltrombopag within the RACE trial.

Key inclusion criteria:

Subject participated in the RACE trial (EudraCT number: 2014-000363-40) during which patient received ATGAM, Cyclosporine A with or without Eltrombopag.

Country:

Principal investigator:

Régis Peffault de Latour, Antonio M. Risitano

EBMT Study coordinator:

Brian Piepenbroek

Study coordinator email:

saawpebmt@lumc.nl